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Background: Anxiety and mood disorders involve a high disease burden and are associated with high
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Data on patients' progress and clinical effectiveness of treatment are assessed at baseline, posttreatment (3. months after baseline), and at 6 and 12. months post-treatment by Routine Outcome
Monitoring (ROM). Cost analysis is performed on the obtained data. Discussion: Since few studies have
investigated both the clinical and cost effectiveness of a stepped-care approach intervention and a
shortened diagnostic ROM method in both anxiety and/or mood disorders within secondary mental health
care, the results of this study might contribute to the improvement of (cost)-effective treatment options
and diagnostic methods for these disorders.
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Abstract
Background: Anxiety and mood disorders involve a high disease burden and are
associated with high economic costs. A stepped-care approach intervention and
abbreviated diagnostic method are assumed to increase effectiveness and efficiency of
the mental healthcare and are expected to reduce economic costs.
Methods: Presented are the rationale, design, and methods of a two-armed randomized
controlled trial comparing ‘treatment as usual’ (TAU) with a brief intensified cognitive
behavioral therapy (CBT) and/or pharmacotherapy. Eligible participants (N= 500) of five
Dutch outpatient Mental Healthcare Centers are randomly assigned to either TAU or to
the experimental condition (brief CBT and/or pharmacotherapy). Data on patients’
progress and clinical effectiveness of treatment are assessed at baseline, post-treatment
(3 months after baseline), and at 6 and 12 months post-treatment by Routine Outcome
Monitoring (ROM). Cost analysis is performed on the obtained data.
Discussion: Since few studies have investigated both the clinical and cost effectiveness
of a stepped-care approach intervention and a shortened diagnostic ROM method in
both anxiety and/or mood disorders within secondary mental health care, the results of
this study might contribute to the improvement of (cost)-effective treatment options and
diagnostic methods for these disorders.
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1. Introduction

Anxiety and mood disorders belong to the most common mental disorders.
Several epidemiological surveys found anxiety and mood disorders to be the
most prevalent class of mental disorders in the general population [1,2]. The
World Health Organization surveys estimated their global lifetime prevalence to
be 14.3% and 10.6%, respectively [1,3]. These disorders frequently start early in
life and tend to have a chronic or relapsing course [4]; moreover, their presence
contributes to a high disease burden for both the patient and their family [3]. They
also have a substantial impact on daily functioning at home/work and on quality
of life [5-8], comparable to the impact and effects of major chronic illnesses
[5,9,10]. Consequently, the economic costs of these disorders for healthcare
systems and society are high [11]. It is estimated that in 2010 the direct and
indirect costs of anxiety and mood disorders in Europe were 74.4 + 113.4 billion
euro, respectively [12]. Earlier studies in the USA and UK reported even higher
estimates [13].
In the last decades, evidence-based treatments for anxiety and mood
disorders have become available, i.e. cognitive behavioral therapy (CBT) and
interpersonal therapy specifically developed for these disorders, as well as
pharmacotherapy (mainly antidepressants) [14,15]. As important differences in
effectiveness between the treatments are absent [13] guidelines were developed
advocating a stepped-care model [16,17]. Moreover, to enhance effectiveness,
for each of these treatments protocols and guidelines became available based on
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those used in randomized controlled trials (RCT) [4,18-20]. Recently, we added
Routine Outcome Monitoring (ROM) to the stepped-care approach to help the
diagnostic process and treatment evaluation [19,20].
It is clear that guidelines, protocols and ROM have the potential to improve
treatment efficacy. However, these improvements may not yet be fully realized as
adherence to the guidelines and protocols remains questionable [17,21-23], even
when ROM is added [19,20]. This implies that treatments last longer, consist of
too many sessions and, thus, unnecessarily prolong suffering and increase
related costs [17,21,22]. Moreover, the current economic situation offers a strong
incentive to make treatments as cost-effective as possible. This applies not only
to the treatments as such, but also to ROM; from an economic point of view ROM
should be as concise as possible.
As most patients are treated in the first phase of the stepped-care model,
it is in this phase that cost reduction is most profitable. Brief therapy is suggested
to be suitable as a first step in a stepped-care model [22,24].
This paper describes an RCT designed to evaluate the effects and costs
of a shortened first treatment in the stepped-care protocol for anxiety and mood
disorders in secondary care, an area where there is a paucity of research.
It consists of time-limited (brief) CBT and/or medication treatment using a
protocol following the multidisciplinary guidelines, but confined to a 7-week period
and a maximum of 7 sessions. Also examined is the feasibility of a shorter, less
labor-intensive ROM. In addition, the cost-effectiveness of the treatment and the
adapted ROM are compared to ‘treatment as usual’ (TAU).
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2. Design and Method

2.1. Study goals
Primary aim of this study is to evaluate the efficacy and effectiveness of a newly
developed time-limited (brief) therapy intervention compared with TAU.
Secondary aim is to evaluate the cost-effectiveness of the experimental
intervention as compared with TAU.
Additionally, the feasibility of a shortened, less work intensive and timeconsuming ROM is evaluated. Patient and therapist satisfaction with the new
intervention is also explored.

2.2. Study design
The study is a pragmatic, two-armed RCT using a parallel group design. Five
Dutch mental health clinics are projected to enroll a total of 500 participants over
an 18-month period of active recruitment. Eligible participants who provide
informed consent are randomly assigned to one of two groups: the control group
(TAU), or the experimental group. Patients in both groups are assessed by ROM
at baseline and after 3 months (post-treatment). Follow-up assessments are
conducted in all patients at 6 and 12 months post-treatment.
Primary and secondary outcomes are assessed by ROM. Primary
outcomes are the scores on the Web Screening Questionnaire (WSQ) and Brief
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Symptom Inventory (BSI). Secondary outcomes are the scores on the other
instruments assessed by ROM (see section 2.8.1 and Table 1).
The design and methodology of this study allows to assess analysis of
equivalency (non-inferiority), since we do not expect to find the introduced
intervention to be superior to TAU.

2.2.1. Control Group (TAU)
Individuals assigned to the control group receive standard psychiatric treatment
called; Treatment As Usual (TAU). TAU varies across centers depending on the
current activities at the participating MHCs. In MHCs, TAU is not strictly
formalized; a multidisciplinary team is free to assign a therapy from a wide range
of evidence-based therapeutic options (including: pharmacotherapy and
psychological treatment, psychosocial interventions, contact with a psychiatric
test nurse) according to the stepped-care approach. The treatment decision is
based on professional experience, taking into account the specific problems and
characteristics of the individual patient. The number of sessions depends on the
therapy that is offered and can be weekly or (almost always) at a lower frequency
of sessions, and are not confined to a maximum of sessions.

2.2.2. Experimental Group
The experimental group receives a brief, intensified cognitive CBT and/or
pharmacotherapy confined to a fixed time period (7 weeks) and a limited number
of weekly sessions (maximum 7 sessions within 7 weeks). The offered CBT and
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pharmacotherapy are described in more detail in section 2.9. An intake and
outtake session are also involved when in the experimental group (described in
section 2.8.2).

2.3. Study setting
The study is conducted at five outpatient mental health clinics from the Dutch
Regional Mental Health Provider (RMHP) Rivierduinen (RD).
RD provides secondary mental health care for an area with over one million
inhabitants. In the Netherlands access to mental health care is easy and is not
limited by insurance or the financial means of the individual patient. Health
insurance is compulsory for all citizens and regulated by the government [25,26].
The Dutch mental healthcare system is organized in a stepped-care manner and
uses evidence-based treatment guidelines. According to a stepped- care
approach a brief but intensive first step is offered and patients who are
insufficiently helped by the initial intervention are allowed to ‘step up’ to
subsequent treatment [16]. The therapeutic principles within the treatment
protocols of the intervention are referred to as a ‘first step’ of a stepped-care
approach.

2.4. Participants
Eligible participants are males and females aged 18 to 65 years, currently
diagnosed with an anxiety and/or depressive disorder as main diagnosis.
Patients with current psychotic or bipolar traits, homicidal or suicidal risk or
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severe social dysfunction, as diagnosed by their general practitioner (GP),
psychiatrist, or as assessed in a diagnostic interview, are excluded. All eligible
subjects need to have adequate understanding of the Dutch language.
Patients with the following DSM IV [27] diagnoses are therefore included:
minor or major depressive disorder (single episode or recurrent), depressive
disorder NAO, dysthemia, panic disorder (with or without agoraphobia), panic
disorder NAO, social phobia, simple phobia, generalized anxiety disorder,
obsessive compulsive disorder, posttraumatic stress disorder (type I or single
trauma), adjustment disorder (with anxiety and/or depressive mood).Co-morbidity
associated with other psychiatric diagnoses (with the exception of psychotic or
bipolar disorder) is allowed in order to establish a clinically relevant, broadly
representative sample.

2.5. Sample size
The sample size was calculated using the method of Cohen [28] and based on
review of the available literature of earlier comparable studies. We aimed at
detecting an equivalence with an acceptable difference of 5% on the primary
outcome measures WSQ and BSI (see section 2.8.1 and Table 1) and a 15%
maximal difference in outcome scores between TAU and the intervention under
the usual assumptions of an α = 0.05 and power of 80%. This results in an
intended total sample size of 500 participants.
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2.6. Recruitment, screening and enrolment procedures
All patients referred by their GP to one of the participating MHCs for the
treatment of anxiety and/or mood disorders are, initially, eligible to participate in
the study.
We adopted the following steps in recruitment: first, all referred patients
are globally screened by an experienced psychiatrist for the presence of
depression and/or anxiety disorders as current, main problem. This global
screening is based on written information provided by the GP containing an
interpretation of the patient’s current health status and referral for further mental
health care; this step does not require face-to-face contact with the patient.
Subsequently, the potentially eligible patients are invited for a first ROM
assessment. Prior to this first ROM assessment, the psychiatric research nurse
conducting the ROM assessment invites the patients to participate in the study.
Those who agree to participate are asked to provide written informed consent.
When informed consent is given, the baseline ROM assessment (T1)
according to the study design is conducted. After completion of this assessment,
participants’ randomization by the research team takes place (see section 2.7).
Depending on the randomized treatment condition, final eligibility is assessed
during the subsequent intake session by means of the inclusion and exclusion
criteria of the study.
Patient enrollment began March 1, 2010 and will end December 31, 2011.
Follow-up assessment is ongoing and is projected to continue until December 31,
2012.
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2.7. Randomization and blinding
After successful screening, provision of written informed consent and completion
of the baseline measurement (T1); (see section 2.6), all eligible participants in
this RCT are randomly assigned to one of two groups: the experimental group or
the control group (TAU). Random allocation was generated by using a variable
blocked design developed by an independent researcher from the Department of
Medical Statistics & BioInformatics, LUMC and derived by computer.
Randomization takes place on the individual level by clinical center (n = 5) and
gender. This procedure is used to increase the likelihood that the distribution
between groups is balanced on the two potentially important confounding
variables and to conceal random allocation sequence.
Participants and clinicians are informed about the outcome of the randomization;
the psychiatric test nurses (assessors) involved in the ROM assessment in the
study, are kept blinded to the randomization condition throughout the entire
study.
Randomization and the subsequent assignment of participants to the intervention
will be performed by the researcher (D.M.), whom is not an assessor.

2.8. Assessment
For both treatment conditions assessment information is obtained in two-fold, as
shown in Figure 1.

 Insert Figure 1 here.
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First, patients participating in this study are assessed by ROM (see 2.8.1.)
at four time intervals: 1) T1 at baseline (start of study), 2) T2 immediately post
treatment (3 months after baseline measurement), 3) T3 6 months post-treatment
(first follow-up measurement), and 4) T4 12 months post-treatment (second
follow-up measurement). The second assessment method is provided by an
intake and outtake evaluation (see also 2.8.2).
The timetable of assessments is shown in Figure 1.

2.8.1. Routine Outcome Measures and feedback
This study is conducted on data collected using ROM [19]. ROM is a monitoring
system for patient care, implemented in 2002 in the outpatient clinics of RD and
the Department of Psychiatry of the LUMC. All outpatients referred to these
clinics by their GP for treatment of a mood, anxiety and/or somatoform disorder,
are assessed by ROM.
ROM periodically measures the presence and severity of psychiatric
symptoms in patients and thereby monitors patients’ progress/changes during
treatment by conducting an extensive battery of psychometric instruments. An
overview of the instruments used in ROM is available at
http://www.lumc.nl/psychiatry/ROM-instruments.
These instruments are routinely assessed at baseline and during
treatment at several time points [19,29]. The baseline assessment also
comprises a standardized diagnostic interview (Dutch version of the Mini-
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International Neuropsychiatric Interview Plus, version 5.0.0) [30,31], the
collection of socio-demographic and socio-economic data, and the administration
of general measures of health and disease-specific severity scales.
Instruments are both self-report and interviewer based. All interviewerbased instruments are carried out by a psychiatric research nurse and the selfreport questionnaires are completed using a touch-screen computer. A webbased software QuestManager (www.psyquestmanager.nl) was developed to
assist the ROM method and is also used in the current study.
Data collected by ROM are provided to the clinician and patient as written
feedback (a brief report) by the psychiatric research nurse. This written feedback
consists of an overview of the main measurement results. Furthermore, a
summary of the diagnostic interview and a summary of the main questionnaires
is given (one or two pages). The clinician shares and discusses these results with
the patient. The assessment outcomes are used to support decision-making for
the future course of the treatment [19,29].
For the present study, all eligible patients are routinely assessed by ROM.
Table 1 lists the instruments used to assess the disorders of interest for the
current study. To further test the hypotheses of the present study, five additional
questionnaires are added to the regular ROM and are indicated (in bold print) in
Table 1.

 Insert Table 1 here.
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Similar to the regular ROM, the baseline assessment comprises the
standardized diagnostic interview, MINI-Plus 5.0.0, and the collection of sociodemographic and socio-economic data.
For the present study, the written ROM feedback depends on the
randomized treatment condition. Clinicians in the experimental group are
provided with minimal information about the results of the questionnaires, i.e. an
overview of the results of the patient’s performance on the two primary outcome
measures: the Web Screening Questionnaire (WSQ) [32] and the Brief Symptom
Inventory (BSI) [33]. The summary of the diagnostic interview and information
about the other measures is left out. Clinicians in the TAU group are provided
with the regular, extensive, feedback about all measurement results.

2.8.2. Intake and outtake
In addition, to examine the progress of patients’ wellbeing and the effectiveness
of the treatment, an intake and outtake session is included in the study design
(Figure 1). Both intake and outtake session are semi- structured and conducted
by the same experienced psychiatrist (see 2.8.5), during one 45 minute
(approximately) session.
The intake takes place before the start of the treatment, after the ROM
baseline measurement. A semi-structured clinical interview, especially designed
for this study, is administered. Compared to a regular intake, this intake session
is protocolized, shorter and more structured. Moreover, the intake aims to ensure
that the patient is eligible to participate in this study by means of the in- and
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exclusion criteria (section 2.4). Personal data, including demographics and the
current clinical picture, are also obtained during this intake session.
The outtake evaluation takes place within (maximally) 2 weeks posttreatment (Figure 1) and is part of a stepped-care approach. The aim of this
semi- structured outtake session is to evaluate if patients are sufficiently helped
by the offered initial intervention or ‘stepping up’ to subsequent (additional)
treatment is necessary. The ‘stepping-up’ is according to clinical experience and
the local and national guidelines as handled by the involved MHC. During the
outtake the progress of the patient’s symptoms and his/her current clinical status
will be assessed. Furthermore, it evaluates the patient’s wellbeing and an ‘end
diagnosis’ is formulated. A possible subsequent treatment plan can be discussed
by patient and clinician.
When the outtake session demonstrates that the achieved treatment effect
is insufficient, the patient is offered to ‘step up’ to additional treatment according
to the treatment guidelines in the same MHC, or elsewhere.

2.9. Treatment
For the current study the following treatment protocols are formulated by the
research team:
1. Pharmacotherapy protocol for mood and/or anxiety disorders (maximum 4
sessions within 7 weeks)
2. Brief Cognitive Behavioral Therapy protocol for depression (minimal 5,
maximum 7 weekly sessions)
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3. Brief Cognitive Behavioral Therapy protocol for anxiety (minimal 5,
maximum 7 weekly sessions)
4. Eye Movement Desensitization and Reprocessing (EMDR) therapy
protocol for post-traumatic stress disorder (PTSD) (maximum 6 sessions
within 7 weeks)

The treatment decision was made by the patient and therapist, based on the
professional experience of the therapist and taking into account the specific
disorder and characteristics of the individual patient, thereby acknowledging the
patient’s preferences as is good practice and according to the common accepted
principles of shared-decision making [34,35].
The treatment protocols are based on the existing treatment guidelines
described in the (multidisciplinary) guidelines in Dutch mental healthcare
[4,36,37] and on acknowledged evidence-based literature [4,38-41]. All treatment
protocols are evaluated during an outtake session (see section 2.8.2.).
Delivering treatment by combining the described protocols is also possible.

2.9.1. Pharmacotherapy for mood and/or anxiety disorders
In the current study the pharmacotherapy protocol for mood disorders and/or
anxiety is characterized by a quick onset and aims to reach an optimal clinical
effect of the used medication, involving rapid stepping up to the most optimal
dose and minimizing the side-effects for patients as much as possible. Patients
are treated with a selective serotonin reuptake inhibitor (SSRI) in 4 sessions

15

within a 7-week period. Medication use is evaluated after this fixed period and
continued when necessary. The protocol provides a scenario for patients when
not using an SSRI (SSRI 1 condition) or, on the other hand, a scenario for
patients with a history of (sufficient and adequate) SSRI use and now starting
with a new different SSRI (SSRI 2 condition). When patients are currently using
an SSRI (as prescribed by their GP), medication is continued and when
necessary adapted according to the pharmacotherapy protocol.

2.9.2. Brief CBT for depression
The brief CBT for depression protocol is focusing on decreasing the depressive
mood of the client and maintain this improvement and based on the cognitive
behavioral therapy manuals/protocols for depression [38,42].
For the current study this protocol is confined to a maximum of 7 weekly sessions
(minimal 5 sessions) within a 7 week time-period. The first 3 sessions of this brief
CBT protocol are dedicated to activation-enhancement and training of social
skills. The last 4 sessions emphasizes tracing and altering irrational cognitions by
challenging them [38,42]. Each treatment session consists of a 45-min face-toface contact and is characterized by a quick onset (no waiting list).

2.9.3. Brief CBT for anxiety
The brief CBT protocol for anxiety disorder is also characterized by a quick onset
(no waiting list) and a maximum number of sessions (minimal 5, maximum 7
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weekly sessions within a 7-week period). Each treatment session consists of a
45-min face-to-face contact.
The main focus of the brief CBT for anxiety protocol is on the core CBT
techniques for the treatment of anxiety disorders: anxiety/tension- reducing
techniques, cognitive techniques and exposure techniques (used when
adequate) [40]. If dysfunctional worrying is interfering, anti-worrying techniques
are offered.

2.9.4. Eye Movement Desensitization and Reprocessing Therapy
The EMDR therapy for the PTSD protocol is characterized by a quick onset (no
waiting list) and a limited number of sessions (a maximum of 6 sessions within 7
weeks). Furthermore, all EMDR sessions comprise a 45-min face-to-face contact.
The EMDR protocol of this study is based on the Dutch Manual EMDR [43] and
approved principles described in the literature [39], or the treatment of PTSD for
patients suffering from a Type I trauma or single trauma.

2.10. Therapist selection, training and supervision
The treatment protocols are performed by experienced clinicians: psychiatrists
and psychologists working at the participating MHCs.
Clinicians working at RD provide treatment in accordance with the
multidisciplinary guidelines of the National Steering Committee describing
evidenced-based treatments for mood and anxiety disorders. The participating
clinicians are all professionally educated and trained in CBT. Years of experience
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ranged between 1- 7 years. They were especially trained to work with the brief
treatment protocols within this study.
The participating clinicians were initially instructed by the research team.
Two hours of instructions were provided for participating clinicians on two
consecutive days. On the first day, a 2-hour instruction was provided for
clinicians involved in the CBT condition. During this instruction, the EMDR
protocol was also introduced. On the subsequent day, a 2-hour instruction was
provided for clinicians involved in providing the pharmacotherapy within this
study.
During these instruction meetings, consensus was achieved on a number
of core elements of the treatments. Furthermore, the content of future supervision
session for all involved clinicians was discussed.
Clinicians in the TAU group received no specific training from the research
team. They provide the usual treatment to the patients; globally following the
available multidisciplinary treatment guidelines, since adherence is questionable.
Furthermore, six certified psychiatric test nurses were trained by the
research team to assess the ROM measurements according to the guidelines of
the study. The research nurses are all trained and certified to assess ROM
measurements.
Instruction was given on the administration and reporting of the ROM
measurements designed for this study. The psychiatric test nurses were informed
about the logistics of the study and how to apply the blinding method used in the
present study.
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Once every 3 months supervision sessions were organized by the
research team for the clinicians and the psychiatric test nurses. Interview
techniques, how to avoid protocol violations and other challenges were discussed
and evaluated.
In addition, unrestricted support is provided to all study clinicians and
psychiatric test nurses via email and through visits made by the research team.

2.11. Fidelity monitoring
All treatment sessions within the brief CBT protocols will be audio-taped,
using a digital voice recorder to ensure treatment protocol fidelity. The taped
treatment sessions will be randomly checked and scored on protocol consistency
and reliability by the research team. Furthermore, therapist adherence and
satisfaction will be monitored using an evaluation questionnaire. This evaluation
questionnaire furthermore monitors the delivery and compliance of the different
treatment protocols since it questions how many sessions were involved and if
treatment was successfully delivered. This evaluation questionnaire, and the list
of the criteria for protocol consistency and reliability, can be obtained from the
corresponding author.

2.12. Statistical analyses
Descriptive statistics will be used to describe the characteristics of the two
groups, and the outcome variables, at the four measurement points. To evaluate
potential group differences at baseline, post-treatment and at the 6 and 12-month
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follow-up measurements, repeated measures analysis will be conducted to
analyze the short and long-term effects between the experimental and control
group.
All analyses will be conducted according to the intention-to-treat (ITT)
approach. Additionally, analysis per protocol will be conducted.
Chi-square analyses and t-tests for independent samples will be used for
data measured on one occasion (e.g. patient satisfaction, therapist satisfaction,
baseline demographic features) to detect possible differences between the two
groups. Differences are considered statistically significant at p < 0.05.
Missing values will be imputed with regression imputation techniques.
Generalized Estimating Equation (GEE) analyses will additionally be performed
on the dataset with missing data and when missing values are imputed. Analyses
adjusting for cluster effects will be performed when analyzing the data.
All analysis will be done using SPSS (version 17, Windows).

2.12.1 Health economics analysis
Cost-effectiveness will be also calculated. An economic evaluation based on the
TIC-P questionnaire (see Table 1) examines the costs and other aspects of the
study protocol. Direct costs per patient in the experimental condition versus the
costs per patient in the control condition will be compared. Costs are validated by
reference; if these references are not available, costs will be estimated by costs
research.
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Cost or product losses are verified by the ‘friction cost method’ [44].The
friction cost method estimates the indirect costs of disease, which explicitly
considers economic circumstances that limit production loss due to disease.
According to this method, these indirect costs mainly occur during the time it
takes to replace a worker, i.e. the friction period [45].

2.13. Approvals and data/safety monitoring
The study protocol was approved by the Medical Ethical Committee (MEC)
of the Leiden University Medical Center (LUMC). After full verbal and written
information about the study, written informed consent was obtained from all
participants at the start of baseline assessment. To safeguard the anonymity of
the patients and to ensure proper handling of the data, processing of all data is in
accordance with a comprehensive protocol: the Psychiatric University Network
REgistration Leiden (PAREL-regulations). The MEC of the LUMC approved the
regulations of this protocol and agreed with this policy [19]. Confidentiality of data
is maintained by using a unique research identification (ID) number for each
participant, which enables to identify individuals without using names. Only a
limited number of persons (researcher) have access to the record that links the
ID number to identifiable information.
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3. Current status and demographics of sample
Data will be collected until at least December 31, 2012. At the time of completion
of this paper, the inclusion period of the study is still ongoing. A total of 161
patients have completed the baseline measurement. Their preliminary sociodemographic and clinical characteristics are presented in Table 2.

> Insert Table 2 here.

These 161 participants are evenly distributed across both groups; 79 in the TAU
group and 82 in the experimental group. Demographic data (educational and
employment status, and ethnic background) are missing for 4 patients. Moreover,
for 12 patients the MINI-Plus diagnostic interview did not lead to a DMS-IV
classification in ROM; therefore, only a clinical diagnosis is available for these
patients.
At baseline there were no significant differences in demographic data
between the two groups. The mean age of the patients is 37.2 (SD 11.5; range
18-65) years, and there is a similar distribution for gender (61.5% female and
38.5% male) in both groups.
Furthermore, the participants comprise a relatively homogeneous group
with common mental disorders, i.e. mainly mood and anxiety disorders. The
majority of the included patients have more than one clinical diagnosis.
At baseline, of all patients 45.3% had an anxiety disorder only, and 37.9%
were diagnosed with depression only. In total, 15.5% of the patients were
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diagnosed with both an anxiety and mood disorder. This distribution was similar
in both treatment arms (Table 2).

4. Discussion
Evidence-based clinical guidelines advocating a stepped-care approach
are available in mental healthcare and have demonstrated success in the
treatment of mood and anxiety disorders [46]. Progress within these steppedcare approaches is carefully monitored and patients are able to ‘step up’ when no
subsequent improvement occurs [16].
However, initiation of and adherence to these recommended and effective
treatments within these guidelines is usually poor [18].The optimal content and
organization of how to provide this stepped care is unclear, and implementation
and acceptability of stepped care as a method of delivering psychological/
psychiatric services has not yet been adopted [21,22]. Little information is
available about how stepped care should be effectively implemented [22] and
only a few randomized trials present convincing evidence and evaluations of both
the cost and clinical effectiveness of this stepped-care model. Most studies
investigated either the cost effectiveness [47,48] or the clinical effectiveness [4952] of stepped care. When simultaneously investigated, the studies examined the
effectiveness of a stepped-care model for patients with either a mood disorder
[53] or an anxiety disorder [54], and only in primary care.
The present study aims to examine the clinical effectiveness and cost
effectiveness of an innovative stepped-care intervention for patients (aged 18-65
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years) with anxiety and/or mood disorders in secondary care. To carefully
monitor the patient’s progress, the ROM method is added.
To our knowledge this is the first long-term study to simultaneously
analyze the clinical and cost effectiveness of a stepped-care approach in the
treatment of both mood and anxiety disorders in a secondary care setting. The
ROM method, monitoring patients’ progress at fixed time intervals with a followup period of 1 year, allows to establish the long-term efficiency expectations of
treatment success and effects on health status and economic costs. Moreover,
for the current study, ROM is shortened and evaluated in terms of feasibility.
Since the baseline characteristics of the participants in both the experimental and
the control group show no significant differences, the study outcomes are
expected to be highly generalizable.
The findings of the present study will have potential implications for
provision of the most convenient form of mental healthcare in the Netherlands.
The offered time-limited, brief intervention could provide valuable information to
help the development of an optimal treatment protocol for patients with anxiety
and/or mood disorders. The limited number of sessions reduces the average
amount of therapist input per patient and, moreover, is an adequate response to
patient preferences for brief psychological interventions [55]. Since the
intervention has not only fewer sessions but also an earlier start after intake, it is
expected to reduce waiting lists; this is a common problem in the provision of
mental healthcare.
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Results of the analyses will allow to compare both the clinical (patient
improvement) and cost effectiveness (economic costs of the intervention)
between the experimental intervention and TAU. Besides answering our primary
question (‘is the experimental intervention at least as effective as providing
regular care, i.e. treatment as usual’) these analyses are expected to provide
insight into how to increase the quality and efficiency of care. The experimental
intervention is expected to reduce costs and increase efficiency on (at least) the
short term. The study design will also provide insight into long-term effects,
possibly encouraging the implementation of an effective stepped-care model in
mental healthcare.
Apart from evaluation of the effectiveness of the intervention, the study
also examines what works best for the individual patient. The broad inclusion
criteria allow the recruitment of patients with a wide range of mood and/or anxiety
disorders. The resulting sample is then broadly representative of the patient
population commonly referred to outpatient mental healthcare centers in the
Netherlands. No indication of a selection bias is expected and, since the ROM
method outlines patient characteristics, the advantages of the experimental
intervention for the individual patient can be clearly assessed.
A major strength of this study is that it is a pragmatic randomized trial. In
such trials, patients and therapist are the same as those encountered in daily
practice. Care is provided by healthcare professionals from the field and, since
the sample of patients is the same as those seen in daily practice, this enhances
the external validity of the study. Moreover, since the stepped-care algorithm
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used covers the whole continuum from enrollment, diagnostics, assessments and
treatment, this study reflects the ‘real’ effects of daily practice thereby allowing
generalization and implementation of any beneficial logistical and organizational
effects in (clinical) practice.
However, this advantage also carries some risks. Besides the logistic
difficulties of implementing a pragmatic randomized trial, it is difficult to maintain
treatment integrity when conducting a study in daily practice. We aim to minimize
this limitation by means of our instruction meetings and supervision sessions for
all clinicians and psychiatric test nurses involved. Moreover, since all treatment
sessions within the brief CBT protocols are audio-taped, treatment protocol
fidelity is closely examined and, hopefully, achieved.
Moreover, since conducting a study in daily practice involves the
possibility of combining CBT and medication therapy and enhances the
possibilities of non-specific effects in therapy, the potential therapeutic benefit of
the intervention can only be formulated with caution.
While the design of the current study addresses many of the limitations of
previous research, a preliminary reflection on further limitations and strengths of
our design is required. Although homogeneous patient groups are expected in
both treatment arms, the control group may have some nonspecific effects on the
expected outcomes. For example, no control is made regarding the number of
visits made by persons in the TAU group to their physicians. Therefore, it is
possible that patients in the control group make fewer visits to their physician or,
in some cases, no visits at all if they are still on a waiting list. Although this does

26

reflect daily practice, we cannot rule out the nonspecific effects of an increased
number of visits and/or attention from physicians as an explanation for the
(possible) better outcomes in the experimental group.
Another limitation concerns the expected dropout rates at the four ROM
measurement assessments, which may affect the results of the study. Although
compliance with the ROM procedure is relatively successful, a 20% dropout rate
is expected at reassessments. In response to these high attrition rates, the
aggregated data are also analyzed according to the intention-to-treat analysis.
This might yield a more valid reflection of the results and conclusions about the
effectiveness of the experimental intervention.
We have described the rationale and design of an RCT examining the
clinical and cost effectiveness of a time-limited, stepped-care based intervention
in the treatment of mood and anxiety disorders. This study is collecting a
substantial amount of data which will improve our understanding of how to
develop effective strategies to adequately diagnose and treat patients with mood
and/or anxiety disorders in secondary care.
If the experimental intervention proves to be as effective as regular care,
this type of intervention could facilitate the growing need of providing the most
optimal and (cost)-efficient mental healthcare. This study will hopefully elucidate
how we can provide the most convenient and adequate mental healthcare for our
patients.
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Intervention

Initial session

End session
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T1

Treatment As Usual
T2

Time
3 months
Initial registration
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Informed consent,
Randomisation and
Baseline Assessment

Fig. 1. Timetable of assessments during the study.
Note: T1 : baseline assessment; T2: post-treatment assessment; T3: first follow-up assessment; T4: second follow-up
assessment.
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Table 1. ROM study measures by time interval
Instrument

Full Name

Domain

Cluster

Typ
ea

Time- intervalb

Reference

T1

T2

T3

T4

AGO

Agoraphobic Cognitions Questionnaire

Psychopath

Spec

SR

X

X

X

X

[56]

BDI-II

Beck Depression Inventory version II

Psychopath

Spec

SR

X

X

X

X

[57]

BSI

Brief Symptom Inventory

Psychopath

Gen

SR

X

X

X

X

[33]

CGI

Clinical Global Impression

Psychopath

Gen

OS

X

X

X

X

[58]

CTQ28

Psychopath

Gen

SR

X

[59]

Psychopath

Gen

SR

X

[60]

DAS -13

Childhood Trauma Questionnaire - 28
Dimensional Assessment of Personality PathologyShort Form
Dysfunctional Attitude Scale - 13

Psychopath

Spec

SR

X

DEMOG

Demographic Inventory

Soc Dem

Gen

SR

X

EVALr

Evaluation Rating

Psychopath

Gen

OS

GAF

Global Assessment of Functioning

Psychopath

Gen

OS

Soc Dem

Gen

SR

X

Cons Satisf

Gen

SR

IES-R

Health Questionnaire
Dutch Mental Healthcare Thermometer
of Appreciation by Clients
Impact of Events Scale - Revised

Psychopath

Spec

SR

X

X

X

X

[64,65]

III (Triple I)

Interpretation of Intrusions Inventory

Psychopath

Spec

SR

X

X

X

X

[66]

LSAS

Liebowitz Social Anxiety Scale

Psychopath

Spec

OS

X

X

X

X

[67]

MASQ

Mood and Anxiety Symptom[32] Questionnaire

Psychopath

Gen

SR

X

X

X

X

[68]

MINI-Plus 5.0.0.

Mini- International Neuropsychiatric Interview Plus 5.0.0.

Psychopath

Gen

OS

X

MRS

Mania Rating Scale

Psychopath

Spec

SR

X

X

X

X

[69]

PADUA/PI-r

Padua Inventory revised

Psychopath

Spec

SR

X

X

X

X

[70]

PAI

Panic Appraisal Inventory

Psychopath

Spec

SR

X

X

X

X

[71]

DAPPsf

c

H_Q

d

Mental Healthcare Thermometer

X

X

X

X

X

X

X

X

X

X

X

X

[61]

[62]

[63]

[30]

PDSS

Panic Disorder Severity Scale

Psychopath

Spec

OS

X

X

X

X

[72]

PSWQ

Penn State Worry Questionnaire

Psychopath

Spec

SR

X

X

X

X

[73]

SF- 36

Short Form Health Survey 36

Psychosoc Func

Gen

SR

X

X

X

X

[74]

SIAS

Social Interaction and Anxiety Scale

Psychopath

Spec

SR

X

X

X

X

[75]

SPS

Social Phobia Scale

Psychopath

Spec

SR

X

X

X

X

[75]

TIC-P

Trimbos/iMTA questionnaire for Costs

Cons Satisf

Gen

SR

X

X

X

X

[76]

associated with Psychiatric Illness

Cost-effect

vCPRS

Abbreviated Comprehensive Psychopathological Rating Scale

Psychopath

Gen

OS

X

X

X

X

[77]

WDQ

Worry Domains Questionnaire
Web Screening Questionnaire
for common mental disorders

Psychopath

Spec

SR

X

X

X

X

[78]

Psychopath

Gen

SR

X

X

X

[32]

WSQ

SR=Self Report; OS=Observer Scale; bT1 : baseline assessment; T2: post treatment assessment; T3: first follow-up assessment; T4: second follow- up assessment; cHealth
Questionnaire H_Q (in Dutch: Gezondheidsvragenlijst); dMental Healthcare Thermometer (in Dutch: GGZ Thermometer)

a

Note: A list of all ROM measures is available at http://www.lumc.nl/psychiatry/ROM-instruments
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Table 2. Socio-demographic and clinical characteristics of the eligible patients at
baseline.
Control group
TAUa
(N=79)
%

Randomized condition
Experimental group

Total

CBTb and/or
Pharmacotherapy
(N=82)

(N=161)

Age in years: mean (SD)

N
37.2 (11.5)

Gender
Male
Female

32
47

40.5
59.5

30
52

36.6
63.4

62
99

Ethnic background c
Dutch
Other ethnicity

74
5

93.7
6.3

72
5

93.6
6.4

146
10

Educational statuscd
Lower education
Higher education

30
49

38.0
62.0

29
48

37.7
62.3

59
97

Employment statusc
Employed
Unemployed/retired
Work-related disability
Other

45
13
17
4

52.0
16.5
21.5
5.1

36
16
18
7

46.8
20.8
23.4
9.1

81
29
35
11

Marital statusc
Married/Cohabitating
Divorced/separated/widow
Single

38
11
30

48.1
13.9
38.0

45
5
27

58.4
6.5
35.1

83
16
57

32
31
11
2

19.9
19.3
6.8
1.2

29
42
14
2

18.0
26.1
8.7
1.2

61
73
25
4

.501
.127
.581
.970

8
26

5.0
16.1

7
21

4.3
13.0

15
47

.729
.308

DSM IVe diagnosis (n, %)
Any Depression
Any Anxiety disorder
Mood and Anxiety disorder
Adjustment disorder (with
anxious and/ore depressive
symptoms)
Post Traumatic Stress Disorder
Other

N
36.0 (12.8)

Pvalue

%
36.6 (12.1)
.609

.967

.968

.546

.226

a
TAU=Treatment As Usual; bCBT=Cognitive Behavioral Therapy; cDemographic data; ethnic background, educational
status and employment status are missing for 4 participants; dLower education= basic education, primary education, no
education at all. Higher education= Higher education, university; eDSM IV=Diagnostic Statistical Manual (of mental
disorders) 4th version.

Note: patients may have more than one diagnosis
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